Canada · Delayed Price · Currency is CAD Burcon NutraScience Earnings Call Transcripts
Fiscal Year 2027
-
Q1 revenue surged 54% sequentially to CAD 1.3 million, with over 40 active customers and strong repeat orders. Growth is driven by high-purity protein demand, capacity expansion, and a new CAD 8.1 million financing to support scaling. Cash flow positivity is targeted by year-end.
Fiscal Year 2026
-
Shareholders approved director elections, the option plan, auditor appointment, and both convertible-debenture resolutions. Management revised 2026 sales guidance to CAD 6 million and expects a CAD 10 million year-end run rate, with cash-flow positivity anticipated inside calendar 2027.
-
Revenue surged nearly sixfold to CAD 2.3 million in fiscal 2026, with double-digit quarter-over-quarter growth and expanding repeat customer sales. Operational milestones included scaling production, launching three new proteins, and achieving record output, positioning for continued strong growth into fiscal 2027.
-
Q3 revenue doubled sequentially, meeting 2025 guidance, with strong recurring sales and over 200 customer projects. Double-digit revenue growth and cash flow positivity are reaffirmed for 2026, supported by a robust sales funnel and recent financing to accelerate capacity and growth.
-
Q2 2026 saw record revenue growth, recurring sales, and strong customer engagement, with guidance for 2025–2026 affirmed and de-risked. New financing initiatives and insider support position the company to capitalize on robust plant protein market demand.
-
Key milestones achieved with first commercial production of pea and fiber proteins, $342,000 in Q1 revenue, and a $6.8M multi-year production agreement. Financial targets for 2025–2026 reaffirmed, with strong customer demand and robust sales funnel supporting growth.
Fiscal Year 2025
-
Significant progress includes a $9.4M fundraise, Galesburg facility acquisition, and first commercial pea protein production. Revenue guidance is $1.1M for 2025, with $10M+ and positive cash flow targeted for 2026. Gross margins are expected to exceed 50% at scale.
-
Raised CAD 9.4 million and secured a U.S. facility with ProMan, enabling full production control and new product launches. Projecting cash flow positivity by 2026, with strong customer interest and a robust pipeline. No major financings planned.
-
A strategic alliance will enable direct production and sales, addressing supply challenges and supporting a capital-light, high-margin model. A rights offering seeks up to CAD 12 million to fund operations, with commercial production targeted for early 2025 and profitability expected in 2026.
-
Achieved first commercial revenues from hemp protein and launched canola protein ahead of schedule, with strong customer demand and over 50 prospects in the pipeline. Profitability is targeted for mid to late 2025, supported by a fully funded business plan and capital-light strategy.
Fiscal Year 2024
-
Fiscal 2024 saw a strategic transformation, improved financials, and the launch of commercial hemp and canola protein products. Recurring revenue is expected in late 2024, with profitability targeted for early 2026. Strong customer demand and a robust funding position support growth plans.